In a previous communication1) data were presented showing that the undialysable component obtained from a bovine bile derivative (BBD) inhibited the growth of the Walker 256 carcinosarcoma. The degree of inhibition was dose related. In the low dose treated group (1.25mg/100g.rat) tumor weights could not be differentiated from those of the controls. In the high dose treated group (10mg/100g rat) most of the tumors regressed to milligram quantities or had undergone extensive necrosis. Histological examination of livers and kidneys of similarly treated controls showed no evidence of toxicity. In larger animals (dogs), the administration, ip of approximately 25 times the anticipated human dose, produced no change in the peripheral blood taken 1 hour and 24 hours post drug administration. These findings motivated further testing of the compound in man. Our human pilot study consisted of seven patients, who had been found refractory to other forms of therapy. They comprised a variety of inoperable malignancies in various stages of progression (Table  1) . 
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